Randomised prostate cancer screening trial: 20 year follow-up

Objective To assess whether screening for prostate cancer reduces prostate cancer specific mortality. Design Population based randomised controlled trial. Setting Department of Urology, Norrköping, and the South-East Region Prostate Cancer Register. Participants All men aged 50-69 in the city of Norrköping, Sweden, identified in 1987 in the National Population Register (n=9026). Intervention From the study population, 1494 men were randomly allocated to be screened by including every sixth man from a list of dates of birth. These men were invited to be screened every third year from 1987 to 1996. On the first two occasions screening was done by digital rectal examination only. From 1993, this was combined with prostate specific antigen testing, with 4 µg/L as cut off. On the fourth occasion (1996), only men aged 69 or under at the time of the investigation were invited. Main outcome measures Data on tumour stage, grade, and treatment from the South East Region Prostate Cancer Register. Prostate cancer specific mortality up to 31 December 2008. Results In the four screenings from 1987 to 1996 attendance was 1161/1492 (78%), 957/1363 (70%), 895/1210 (74%), and 446/606 (74%), respectively. There were 85 cases (5.7%) of prostate cancer diagnosed in the screened group and 292 (3.9%) in the control group. The risk ratio for death from prostate cancer in the screening group was 1.16 (95% confidence interval 0.78 to 1.73). In a Cox proportional hazard analysis comparing prostate cancer specific survival in the control group with that in the screened group, the hazard ratio for death from prostate cancer was 1.23 (0.94 to 1.62; P=0.13). After adjustment for age at start of the study, the hazard ratio was 1.58 (1.06 to 2.36; P=0.024). Conclusions After 20 years of follow-up the rate of death from prostate cancer did not differ significantly between men in the screening group and those in the control group. Trial registration Current Controlled Trials, ISRCTN06342431.

[1]  O. Löfman,et al.  Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. , 2004, European urology.

[2]  H. D. de Koning,et al.  Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer , 2009, British Journal of Cancer.

[3]  J. Ludvigsson,et al.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research , 2009, European Journal of Epidemiology.

[4]  Monique J. Roobol,et al.  Mortality Results from a Randomized ProstateCancer Screening Trial , 2009 .

[5]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[6]  E. Varenhorst,et al.  Validity of a Population-Based Cancer Register in Sweden An Assessment of Data Reproducibility in the South-East Region Prostate Cancer Register , 2003, Scandinavian journal of urology and nephrology.

[7]  Peter C Albertsen,et al.  The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis. , 2010, Urology.

[8]  E. Varenhorst,et al.  The impact of prostate‐specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate , 2008, Cancer.

[9]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[10]  E. Varenhorst,et al.  Costs and benefits of early detection of prostatic cancer. , 1990, Health policy.

[11]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[12]  Jaime Pujadas Oláno,et al.  Natural history of early localized prostate cancer. , 2004, JAMA.

[13]  O. Löfman,et al.  Inter-observer variation in assessment of the prostate by digital rectal examination. , 1993, British journal of urology.

[14]  E. Varenhorst,et al.  Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002. , 2006, European urology.

[15]  P. Stattin,et al.  Non‐systematic screening for prostate cancer in SwedenSurvey from the National Prostate Cancer Registry , 2003, Scandinavian journal of urology and nephrology.

[16]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[17]  Therese Miller,et al.  Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[18]  Katja Fall,et al.  Reliability of death certificates in prostate cancer patients , 2008, Scandinavian journal of urology and nephrology.

[19]  M. Britton,et al.  IMPACT OF HEALTH TECHNOLOGY ASSESSMENTS , 2002, International Journal of Technology Assessment in Health Care.

[20]  Laura Esserman,et al.  Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.

[21]  P Carlsson,et al.  Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. , 1990, BMJ.

[22]  O. Löfman,et al.  Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. , 1992, Acta oncologica.

[23]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[24]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[25]  M. Roobol,et al.  ERSPC and PLCO prostate cancer screening studies: what are the differences? , 2010, European urology.